Cognitive behavioral group therapy vs phenelzine therapy for social phobia 12-week outcome

Archives of General Psychiatry

Volumn 55, Issue 12, 1998, Pages 1133-1141

  Heimberg, Richard G ^a,c   Liebowitz, Michael R ^b   Hope, Debra A ^a,d   Schneier, Franklin R ^b   Holt, Craig S ^a,e   Welkowitz, Lawrence A ^b,f   Juster, Harlan R ^a   Campeas, Raphael ^b   Bruch, Monroe A ^a   Cloitre, Marylene ^b,g   Fallon, Brian ^b   Klein, Donald F ^b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f KEENE STATE COLLEGE   (United States)

^g Payne Whitney Psychiatric Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; PHENELZINE; PLACEBO;

ADULT; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GROUP THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; SOCIAL PHOBIA; SOCIAL SUPPORT; TREATMENT OUTCOME;

EID: 0031736386     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.55.12.1133     Document Type: Article

References (69)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
2. Hazen AL, Stein MB. Clinical phenomenology and comorbidity. In: Stein MB, ed. Social Phobia: Clinical and Research Perspectives. Washington, DC: American Psychiatric Press; 1995:3-41.
3. Öst L-G. Age of onset in different phobias. J Abnorm Psychol. 1987;96:223-229.
4. Reich J, Goldenberg I, Vasile R, Goisman R, Keller M. A prospective follow-along study of the course of social phobia. Psychiatry Res. 1994;54:249-258.
5. Magee WJ, Eaton WW, Wittchen H-U, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996;53:159-168.
6. Schneier FR, Johnson J, Hornig C, Liebowitz MR, Weissman MM. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992;49:282-288.
7. Davidson JRT, Hughes DL, George LK, Blazer DG. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol Med. 1993;23:709-718.
8. Liebowitz MR, Gorman JM, Fyer AJ, Klein DF. Social phobia: review of a neglected anxiety disorder. Arch Gen Psychiatry. 1985;42:729-736.
9. Turner SM, Beidel DC, Dancu CV, Keys DJ. Psychopathology of social phobia and comparison to avoidant personality disorder. J Abnorm Psychol. 1986;95:389-394.
10. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, Street L, DelBene D, Liebowitz MR. Functional impairment in social phobia. J Clin Psychiatry. 1994;55:322-331.
11. van Vliet IM, den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: a double blind controlled study with fluvoxamine. Psychopharmacology. 1994;115:128-134.
12. Katzelnick DJ, Kobak KAY, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995;152:1368-1371.
13. Stein MB, Chartier MJ, Hazen AL, Croft CDL, Chale RA, Coté D, Walker JA. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol. 1996; 16:218-222.
14. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized, controlled study. JAMA. 1998;280:708-713.
15. Davidson JRT, Potts NLS, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13:423-428.
16. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, Klein DF. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry. 1992;49:290-300.
17. Tumer SM, Beidel DC, Jacob R. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol. 1994;62:350-358.
18. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry. 1991;48:938-945.
19. Clark DB, Agras WS. The assessment and treatment of performance anxiety in musicians. Am J Psychiatry. 1991;148:598-605.
20. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia: a controlled study with moclobemide and PZ. Br J Psychiatry. 1992;161:353-360.
21. Noyes R, Moroz G, Davidson JRT, Liebowitz MR, Davidson A, Siegel J, Bell J, Cain JW, Curlik SM, Kent TA, Lydiard RB, Mallinger AG, Pollack MH, Rapaport M, Rasmussen SA, Hedges D, Schweizer E, Uhlenhuth EH. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997;17:247-254.
22. Fahlén T, Nilsson HL, Borg K, Humble M, Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. Acta Psychiatr Scand. 1995;92:351-358.
23. Lott M, Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Katz RJ, Schaettle SC. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol. 1997;17:255-260.
24. International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci. 1997;247:71-80.
25. Heimberg RG, Juster HR. Cognitive behavioral treatment: literature review. In: Heimberg R, Liebowitz M, Hope D, Schneier F, eds. Social Phobia: Diagnosis, Assessment and Treatment. New York, NY: Guilford Press: 1995:261-309.
26. Feske U, Chambless DL. Cognitive behavioral versus exposure only treatment for social phobia: a meta-analysis. Behav Ther. 1995;26:695-720.
27. Butler G, Wells A. Cognitive behavioral treatments: clinical applications. In: Heimberg R, Liebowitz M, Hope D, Schneier F, eds. Social Phobia: Diagnosis, Assessment and Treatment. New York, NY: Guilford Press; 1995:310-333.
28. Butler G, Cullington A, Munby M, Amies P, Gelder M. Exposure and anxiety management in the treatment of social phobia. J Consult Clin Psychol. 1984;52:642-650.
29. Mattick RP, Peters L. Treatment of severe social phobia: effects of guided exposure with and without cognitive restructuring. J Consult Clin Psychol. 1988; 56:251-260.
30. Mattick RP, Peters L, Clarke JC. Exposure and cognitive restructuring for social phobia: a controlled study. Behav Ther. 1989;20:3-23.
31. Chambless DL, Gillis MM. Cognitive therapy of anxiety disorders. J Consult Clin Psychol. 1993;61:248-260.
32. Heimberg RG, Juster HR, Hope DA, Mattia JI. Cognitive behavioral group treatment for social phobia: description, case presentation and empirical support. In: Stein MB, ed. Social Phobia: Clinical and Research Perspectives. Washington, DC: American Psychiatric Press; 1995:293-321.
33. Heimberg RG, Juster HR. Treatment of social phobia in cognitive behavioral groups. J Clin Psychiatry. 1994;55(suppl 6):38-46.
34. Heimberg RG, Becker RE, Goldfinger K, Vermilyea JA. Treatment of social phobia by exposure, cognitive restructuring, and homework assignments. J Nerv Ment Dis. 1985;173:236-245.
35. Heimberg RG, Dodge CS, Hope DA, Kennedy CR, Zollo L, Becker RE. Cognitive behavioral group treatment of social phobia: comparison with a credible placebo control. Cogn Ther Res. 1990;14:1-23.
36. Heimberg RG, Salzman D, Holt CS, Blendell K. Cognitive behavioral group treatment of social phobia: effectiveness at 5-year follow-up. Cogn Ther Res. 1993; 17:325-339.
37. Hope DA, Heimberg RG, Bruch MA. Dismantling cognitive-behavioral group therapy for social phobia. Behav Res Ther. 1995;33:637-650.
38. Brown EJ, Heimberg RG, Juster HR. Social phobia subtype and avoidant personality disorder: effect on severity of social phobia, impairment, and outcome of cognitive-behavioral treatment. Behav Ther. 1995;26:467-486.
39. Leung AW, Heimberg RG. Homework compliance, perceptions of control, and outcome of cognitive-behavioral treatment of social phobia. Behav Res Ther. 1996; 34:423-432.
40. Bruch MA, Heimberg RG, Hope DA. States of mind model and cognitive change in treated social phobics. Cogn Ther Res. 1991;15:429-441.
41. Hope DA, Herbert JD, White C. Diagnostic subtype, avoidant personality disorder, and efficacy of cognitive-behavioral group therapy for social phobia. Cogn Ther Res. 1995;19:399-417.
42. Edelman R, Chambless DL. Adherence during sessions and homework in cognitive-behavioral group treatment of social phobia. Behav Res Ther. 1995;33:573-577.
43. Heirnberg RG. Specific issues in the cognitive-behavioral treatment of social phobia. J Clin Psychiatry. 1993;54(suppl 12):36-45.
44. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association: 1987.
45. DiNardo PA, Barlow DH. Anxiety Disorders Interview Schedule-Revised. Albany, NY: Graywind Publications; 1988.
46. DiNardo PA, Moras K, Barlow DH, Rapee RM, Brown TA. Reliability of DSM-III-R anxiety disorder categories: using the Anxiety Disorders Interview Schedule-Revised. Arch Gen Psychiatry. 1993;50:251-256.
47. Mannuzza S, Fyer AJ, Endicott, J, Klein DF. Schedule for Affective Disorders and Schizophrenia-Lifetime version (modified for the study of anxiety disorders) (SADS-LA): rationale and conceptual development. J Psychiat Res. 1986;20:317-325.
48. Spitzer RL, Williams JBW, Gibbon M, First M. The Structured Clinical Interview for DSM-III-R(SCID), I: history, rationale, and development. Arch Gen Psychiatry. 1992;49:624-629.
49. Fawcett J, Epstein P, Fiester SJ, Elkin I, Autry JH. Clinical management -imipramine/placebo administration manual: NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull. 1987;23:309-324.
50. Sweet RA, Brown EJ, Heimberg RG, Ciafre L, Scanga D, Cornelius J, Dube S, Forsyth KM, Holt CS. Monoamine oxidase inhibitor dietary restrictions: what are we asking patients to give up? J Clin Psychiatry. 1995;56:196-201.
51. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141-173.
52. Munjack DJ, Bruns J, Baltazar PL, Brown R, Leonard M, Nagy R, Koek R, Crocker B, Schafer S. A pilot study of buspirone in the treatment of social phobia. J Anxiety Disord. 1991;5:87-98.
53. Reich J, Yates W. A pilot study of the treatment of social phobia with alprazolam. Am J Psychiatry. 1988;145:590-594.
54. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, Liebowitz MR. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med. In press.
55. Heimberg RG, Mueller GP, Holt CS, Hope DA, Liebowitz MR. Assessment of anxiety in social interactions and being observed by others: the Social Interaction Anxiety Scale and the Social Phobia Scale. Behav Ther. 1992;23:53-73.
56. Loranger AW. Personality Disorders Examination Manual. Yonkers, NY: DV Communications: 1988.
57. Loranger AW, Sartorius N, Andreoli A, Berger P, Buchheim P, Channabasavanna SM, Coid B, Dahl A, Diekstra RFW, Ferguson B, Jacobsberg LB, Mombour W, Pull C, Ono Y, Regier DA. The International Personality Disorders Examination: the World Health Organization/Alcohol, Drug Abuse, and Mental Health Administration international pilot study of personality disorders. Arch Gen Psychiatry. 1994;51:215-224.
58. Watson D, Friend R. Measurement of social-evaluative anxiety. J Consult Clin Psychol. 1969;33:448-457.
59. Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther. 1979;17:263-267.
60. Oei TPS, Moylan A, Evans L. Validity and clinical utility of the Fear Questionnaire for anxiety disorder patients. Psychol Assess. 1991;3:391-397.
61. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther. 1998;36:455-470.
62. Brown EJ, Turovsky J, Heimberg RG, Juster HR, Brown TA, Barlow DH. Validation of the Social Interaction Anxiety Scale and the Social Phobia Scale across the anxiety disorders. Psychol Assess. 1997;9:21-27.
63. Safren SA, Turk CL, Heimberg RG. Factor structure of the Social Interaction Anxiety Scale and the Social Phobia Scale. Behav Res Ther. 1998;46:443-453.
64. Ries BJ, McNeil DW, Boone ML, Turk CL, Carter LE, Heimberg RG. Assessment of contemporary social phobia verbal report instruments. Behav Res Ther. 1998; 36:983-994.
65. Derogatis LR. SCL-90 Administration. Scoring and Procedures Manual for the Revised Version. Baltimore. Md; Johns Hopkins University Press; 1977.
66. Holt CS, Heimberg RG. The Reaction to Treatment Questionnaire: measuring treatment credibility and outcome expectancies. Behav Ther. 1990;13:213-214, 222.
67. Stokes JP. Toward an understanding of cohesion in personal change groups. Int J Group Psychother. 1983;33:449-467.
68. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
69. Safren SA, Heimberg RG, Brown EJ, Holle C. Quality of life in social phobia. Depress Anxiety. 1997;4:126-133.